Tonix Pharmaceuticals Holding (TNXP) Receivables - Net (2023 - 2026)

Tonix Pharmaceuticals Holding's Receivables - Net history runs 4 years deep, the most recent figure standing at $8.8 million for Q1 2026.

• On a quarterly basis, Receivables - Net rose 166.3% year-over-year to $8.8 million in Q1 2026; TTM through Mar 2026 was $8.8 million, a 166.3% increase from a year earlier, with the FY2025 full-year figure at $6.3 million, up 70.27% from the prior year.
• Receivables - Net grew to $8.8 million in Q1 2026 per TNXP's latest filing, from $6.3 million in the prior quarter.
• Across five years, Receivables - Net topped out at $8.8 million in Q1 2026 and bottomed at $1.6 million in Q3 2023.
• The 4-year median for Receivables - Net is $3.4 million (2024), against an average of $3.9 million.
• Across the five-year window, Receivables - Net tumbled 30.52% in 2025 and surged 166.3% in 2026, its largest moves.
• Year by year, Receivables - Net stood at $4.6 million in 2023, then retreated by 19.76% to $3.7 million in 2024, then soared by 70.27% to $6.3 million in 2025, then soared by 40.65% to $8.8 million in 2026.
• Per Business Quant, the three latest TNXP Receivables - Net figures stand at $8.8 million (Q1 2026), $6.3 million (Q4 2025), and $3.5 million (Q3 2025).